Pipelines

alleo logo
*
Target ID
Hit-ID
Hit-to-Lead
Lead-ID
Lead Opt
Pre-IND
Alzheimer Type I
IMM-AO.01
Target ID
Hit-ID
Hit-to-Lead
Lead-ID
Lead Opt
Pre-IND

Title

42%
IMM-AO.02
Target ID
Hit-ID
Hit-to-Lead
Lead-ID
Lead Opt
Pre-IND

Title

33%
IMM-AO.03
Target ID
Hit-ID
Hit-to-Lead
Lead-ID
Lead Opt
Pre-IND

Title

33%
Alzheimer Type II
IMM-AO.04
Target ID
Hit-ID
Hit-to-Lead
Lead-ID
Lead Opt
Pre-IND

Title

25%
IMM-AO.05
Target ID
Hit-ID
Hit-to-Lead
Lead-ID
Lead Opt
Pre-IND

Title

25%
IMM-AO.06
Target ID
Hit-ID
Hit-to-Lead
Lead-ID
Lead Opt
Pre-IND

Title

25%
Alzheimer Type I
IMM-AO.07
Target ID
Hit-ID
Hit-to-Lead
Lead-ID
Lead Opt
Pre-IND

Title

25%
IMM-AO.08
Target ID
Hit-ID
Hit-to-Lead
Lead-ID
Lead Opt
Pre-IND

Title

25%
IMM-AO.09
Target ID
Hit-ID
Hit-to-Lead
Lead-ID
Lead Opt
Pre-IND

Title

25%
Alzheimer Type II
IMM-AO.10
Target ID
Hit-ID
Hit-to-Lead
Lead-ID
Lead Opt
Pre-IND

Title

25%
IMM-AO.11
Target ID
Hit-ID
Hit-to-Lead
Lead-ID
Lead Opt
Pre-IND

Title

25%
IMM-AO.12
Target ID
Hit-ID
Hit-to-Lead
Lead-ID
Lead Opt
Pre-IND

Title

25%

For most Alzheimer’s patients, there is no clear trajectory of disease progression or worsening symptoms. In fact, even clinical presentation can be widely different from individual to individual, suggesting that Alzheimer’s is less of a disease and more of a syndrome. Integrating brain gene expression and AD marker data offers the potential to stratify patients into subgroups with unique biology and identify targets specific to these subgroups.